Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

PHASE2CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
GastroparesisDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.

DRUG

10mg TZP-102

One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks

DRUG

20mg TZP-102

Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients

Trial Locations (52)

1200

Tranzyme Investigational Site, Brussels

5000

Tranzyme Investigational Site, Odense

5021

Tranzyme Investigational Site, Bergen

8000

Tranzyme Investigational Site, Aarhus

8310

Tranzyme Investigational Site, Bruges

19140

Tranzyme Investigational Site, Philadelphia

27103

Tranzyme Investigational Site, Winston-Salem

27612

Tranzyme Investigational Site, Raleigh

28144

Tranzyme Investigational Site, Salisbury

28304

Tranzyme Investigational Site, Fayetteville

32127

Tranzyme Investigational Site, Port Orange

32168

Tranzyme Investigational Site, New Smyrna Beach

32256

Tranzyme Investigational Site, Jacksonville

33016

Tranzyme Investigational Site, Hialeah

33144

Tranzyme Investigational Site, Miami

33183

Tranzyme Investigational Site, Miami

34450

Tranzyme Investigational Site, Inverness

35801

Tranzyme Investigational Site, Huntsville

38305

Tranzyme Investigational Site, Jackson

45136

Tranzyme Investigational Site, Essen

46016

Tranzyme Investigational Site, Anderson

55116

Tranzyme Investigational Site, Mainz

60453

Tranzyme Investigational Site, Oak Lawn

65265

Tranzyme Investigational Site, Mexico

66160

Tranzyme Investigational Site, Kansas City

70191

Tranzyme Investigational Site, Stuttgart

71201

Tranzyme Investigational Site, Monroe

72117

Tranzyme Investigational Site, Little Rock

72401

Tranzyme Investigational Site, Jonesboro

73104

Tranzyme Investigational Site, Oklahoma City

77034

Tranzyme Investigational Site, Houston

79905

Tranzyme Investigational Site, El Paso

85710

Tranzyme Investigational Site, Tucson

90822

Tranzyme Investigational Site, Long Beach

93003

Tranzyme Investigational Site, Ventura

94305

Tranzyme Investigational Site, Stanford

97210

Tranzyme Investigational Site, Portland

98405

Tranzyme Investigational Site, Tacoma

02215

Tranzyme Investigational Site, Boston

B-9000

Tranzyme Investigational Site, Ghent

Unknown

Tranzyme Investigational Site, Gentofte Municipality

Tranzyme Investigational Site, Tampere

Tranzyme Investigational Site, Bialystok

Tranzyme Investigational Site, Krakow

Tranzyme Investigational Site, Lodz

Tranzyme Investigational Site, Olsztyn

Tranzyme Investigational Site, Stockholm

Tranzyme Investigational Site, Uppsala

06151

Tranzyme Investigational Site, Porvoo

85-094

Tranzyme Investigational Site, Bydgoszcz

25-035

Tranzyme Investigational Site, Kielce

02-097

Tranzyme Investigational Site, Warsaw

All Listed Sponsors
lead

Tranzyme, Inc.

INDUSTRY

NCT01452815 - Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis | Biotech Hunter | Biotech Hunter